Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 1/20 | 1.00 |
| ▸ | PADI4 | Q9UM07 | 17/20 | 0.83 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.80 |
| ▸ | IKBKB | O14920 | 2/20 | 0.64 |
| ▸ | CHUK | O15111 | 2/20 | 0.64 |
| ▸ | AKT1 | P31749 | 2/20 | 0.64 |
| ▸ | AKT2 | P31751 | 2/20 | 0.64 |
| ▸ | AKT3 | Q9Y243 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6492645 | 1.00 | MAPK10 (1.00) | MAPK10PADI4ASAH1IKBKBCHUK | |
| SCHEMBL19952787 | 0.91 | PADI4 (1.00) | MAPK10PADI4ASAH1IKBKBCHUK | |
| SCHEMBL23498282 | 0.89 | MAPK10 (0.81) | MAPK10PADI4ASAH1IKBKBCHUK | |
| SCHEMBL29627099 | 0.89 | PADI4 (1.00) | MAPK10PADI4ASAH1 | |
| SCHEMBL18426912 | 0.89 | PADI4 (1.00) | MAPK10PADI4ASAH1 | |
| SCHEMBL18426910 | 0.89 | PADI4 (1.00) | MAPK10PADI4ASAH1 | |
| SCHEMBL30139088 | 0.89 | PADI4 (1.00) | MAPK10PADI4ASAH1 | |
| SCHEMBL23510917 | 0.88 | MAPK10 (0.78) | MAPK10PADI4ASAH1IKBKBCHUK | |
| SCHEMBL23468075 | 0.85 | PADI4 (0.81) | MAPK10PADI4ASAH1 | |
| SCHEMBL23468073 | 0.85 | PADI4 (1.00) | MAPK10PADI4ASAH1IKBKBCHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050165053-A1 | Substituted4-aryl-3-(3-aryl-1-oxo-2-propenyl)-2(1h)-quinolinones and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2005-07-28 | — | — | US | claimed |
| US-20250367471-A1 | PERFUSION MODULATED TUMOR DOSE SCULPTING WITH SINGLE DOSE RADIOTHERAPY | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2025-12-04 | — | — | US | disclosed |
| US-12214218-B2 | Perfusion modulated tumor dose sculpting with single dose radiotherapy | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2025-02-04 | — | — | US | disclosed |
| WO-2022261752-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PARKER ALEX (CA) | 2022-12-22 | — | — | WO | disclosed |
| US-20220387358-A1 | CERAMIDE ANALOG SACLAC MODULATES SPHINGOLIPID LEVELS AND MCL-1 SPLICING TO INDUCE APOPTOSIS IN ACUTE MYELOID LEUKEMIA | UNIV VIRGINIA PATENT FOUNDATION (US) | 2022-12-08 | — | — | US | disclosed |
| US-20220296926-A1 | PERFUSION MODULATED TUMOR DOSE SCULPTING WITH SINGLE DOSE RADIOTHERAPY | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-09-22 | — | — | US | disclosed |
| US-20220288004-A1 | TREATMENT AND PREVENTION OF AGING RELATED-DISEASE AND/OR AGING BY THE INHIBITION OF SPHINGOLIPIDS | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2022-09-15 | — | — | US | disclosed |
| EP-4003508-A1 | PERFUSION MODULATED TUMOR DOSE SCULPTING WITH SINGLE DOSE RADIOTHERAPY | Memorial Sloan Kettering Cancer Center (US) | 2022-06-01 | — | — | EP | disclosed |
| US-20050165053-A1 | Substituted4-aryl-3-(3-aryl-1-oxo-2-propenyl)-2(1h)-quinolinones and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2005-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220296926-A1 | PERFUSION MODULATED TUMOR DOSE SCULPTING WITH SINGLE DOSE RADIOTHERAPY | TP53, CTPS1, TSG101 | MAPK10 4263/4885PADI4 3388/4885ASAH1 770/4885 |
| US-20220288004-A1 | TREATMENT AND PREVENTION OF AGING RELATED-DISEASE AND/OR AGING BY THE INHIBITION OF SPHINGOLIPIDS | SMPD3, SMPD2, SMPD1 | MAPK10 2290/4885PADI4 1090/4885ASAH1 9/4885 |
| US-12214218-B2 | Perfusion modulated tumor dose sculpting with single dose radiotherapy | TP53, CTPS1, TSG101 | MAPK10 4263/4885PADI4 3388/4885ASAH1 770/4885 |
| US-20050165053-A1 | Substituted4-aryl-3-(3-aryl-1-oxo-2-propenyl)-2(1h)-quinolinones and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP4, CASP3, CASP2 | MAPK10 2917/4885PADI4 1662/4885ASAH1 2749/4885 |
| US-20250367471-A1 | PERFUSION MODULATED TUMOR DOSE SCULPTING WITH SINGLE DOSE RADIOTHERAPY | TP53, CTPS1, TSG101 | MAPK10 4263/4885PADI4 3388/4885ASAH1 770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.